MX2021009326A - Pridopidina de dosis baja para mal de parkinson y otras enfermedades asociadas con parkinsonismo. - Google Patents

Pridopidina de dosis baja para mal de parkinson y otras enfermedades asociadas con parkinsonismo.

Info

Publication number
MX2021009326A
MX2021009326A MX2021009326A MX2021009326A MX2021009326A MX 2021009326 A MX2021009326 A MX 2021009326A MX 2021009326 A MX2021009326 A MX 2021009326A MX 2021009326 A MX2021009326 A MX 2021009326A MX 2021009326 A MX2021009326 A MX 2021009326A
Authority
MX
Mexico
Prior art keywords
parkinsonism
low dose
parkinson
disease
diseases associated
Prior art date
Application number
MX2021009326A
Other languages
English (en)
Inventor
Michal Geva
Michael Hayden
Nilsson Angela Cenci
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of MX2021009326A publication Critical patent/MX2021009326A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona un método para tratar Parkinsonismo o síntoma del mismo mediante pridopidina en dosis bajas.
MX2021009326A 2019-02-04 2020-02-04 Pridopidina de dosis baja para mal de parkinson y otras enfermedades asociadas con parkinsonismo. MX2021009326A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962800803P 2019-02-04 2019-02-04
PCT/IL2020/050134 WO2020161707A1 (en) 2019-02-04 2020-02-04 Low dose pridopidine for parkinson's disease and other diseases associated with parkinsonism

Publications (1)

Publication Number Publication Date
MX2021009326A true MX2021009326A (es) 2021-09-08

Family

ID=71947139

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009326A MX2021009326A (es) 2019-02-04 2020-02-04 Pridopidina de dosis baja para mal de parkinson y otras enfermedades asociadas con parkinsonismo.

Country Status (10)

Country Link
US (1) US20220193059A1 (es)
EP (1) EP3920924A4 (es)
JP (1) JP2022519103A (es)
CN (1) CN113395964A (es)
AU (1) AU2020218158B2 (es)
BR (1) BR112021015346A2 (es)
CA (1) CA3125893C (es)
IL (1) IL285160A (es)
MX (1) MX2021009326A (es)
WO (1) WO2020161707A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021215396A1 (en) * 2020-02-03 2022-09-29 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013086425A1 (en) * 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
EP3590512A1 (en) * 2015-02-25 2020-01-08 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat epilepsy

Also Published As

Publication number Publication date
JP2022519103A (ja) 2022-03-18
CA3125893C (en) 2024-03-19
US20220193059A1 (en) 2022-06-23
AU2020218158A1 (en) 2021-08-19
CN113395964A (zh) 2021-09-14
EP3920924A4 (en) 2022-11-16
IL285160A (en) 2021-09-30
BR112021015346A2 (pt) 2021-10-05
EP3920924A1 (en) 2021-12-15
CA3125893A1 (en) 2020-08-13
AU2020218158B2 (en) 2023-08-03
WO2020161707A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
GEP20227446B (en) New catecholamine prodrugs for use in treatment of parkinson's disease
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
MX2019005594A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia.
JOP20190147A1 (ar) تركيبات حمض أميني وطرق لمعالجة أمراض واضطرابات العضلات
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
PH12017500032A1 (en) Improved a� protofibril binding antibodies
MX2020002884A (es) Método y composición neuroprotectora mejorada para tratar afecciones neurológicas.
MX2018004170A (es) Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos.
MX2021006901A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
MX2019006495A (es) Tratamiento de enfermedades neurologicas.
MX2019012086A (es) Composiciones y métodos para tratar o prevenir trastornos relacionados con la permeabilidad intestinal.
BR112022003956A2 (pt) Anticorpos anti-cd73
MX2020012979A (es) Métodos para aumentar la exposición al plasma de sepiapterina.
JOP20220092A1 (ar) جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر
BR112021011729A2 (pt) Tubulisinas e conjugados de proteína-tubulisina
WO2018178243A3 (en) Dihydrotetrabenazine for use in the treatment a movement disorder
MX2017005522A (es) Tratamiento novedoso de la cornea usando laminina.
MX2021006682A (es) Inhibidores de descarboxilasa para el tratamiento de la enfermedad de parkinson.
MX2020009532A (es) Oligonucleotidos modificados para uso en el tratamiento de tauopatias.
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
MX2021009326A (es) Pridopidina de dosis baja para mal de parkinson y otras enfermedades asociadas con parkinsonismo.
JOP20200041A1 (ar) تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي
MX2021011151A (es) Fitoecdisonas y los derivados de las mismas para su uso en el tratamiento de enfermedades neuromusculares.